ReviewCellular immunology2021
Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases.
Review in Cellular immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Alternatively activated neutrophils limit T cell-driven neuroinflammation.Journal of neuroinflammation · 2026Article
- Nanoparticle-boosted myeloid-derived suppressor cell therapy for immune reprogramming in multiple sclerosis.Science advances · 2025Article
- A donor PD-1Signal transduction and targeted therapy · 2025Article
- Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs.Science (New York, N.Y.) · 2024Article
- Resolvin D2/GPR18 signaling enhances monocytic myeloid-derived suppressor cell function to mitigate abdominal aortic aneurysm formation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- MerTK-dependent efferocytosis by monocytic-MDSCs mediates resolution of ischemia/reperfusion injury after lung transplant.JCI insight · 2024Article
- Myeloid-derived suppressor cells in influenza virus-induced asthma exacerbation.Frontiers in immunology · 2024Article
- Engaging natural regulatory myeloid cells to restrict T-cell hyperactivation-induced liver inflammation via extracellular vesicle-mediated purine metabolism regulation.Theranostics · 2024Article
- Here, There, and Everywhere: Myeloid-Derived Suppressor Cells in Immunology.Journal of immunology (Baltimore, Md. : 1950) · 2023Review
- Local and Systemic Injections of Human Cord Blood Myeloid-Derived Suppressor Cells to Prevent Graft Rejection in Corneal Transplantation.Biomedicines · 2022Article
- The Function and Therapeutic Implications of TNF Signaling in MDSCs.Biomolecules · 2022Review
- A novel immunochemotherapy based on immunogenicity-activated and immunosuppression-reversed biomimetic nanoparticles.RSC advances · 2022Article
- Recent Advances in Cell Therapeutics for Systemic Autoimmune Diseases.Immune network · 2022Review
- Aging Affects the Role of Myeloid-Derived Suppressor Cells in Alloimmunity.Frontiers in immunology · 2022Review
- Beyond immunosuppressive effects: dual roles of myeloid-derived suppressor cells in bone-related diseases.Cellular and molecular life sciences : CMLS · 2021Review
- Glucosamine Interferes With Myelopoiesis and Enhances the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells.Frontiers in nutrition · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells, which have been characterized for their immunosuppressive capacity through multiple mechanisms. These cells have been extensively studied in the field of tumor immunity. Emerging evidence has highlighted its essential role in maintaining immune tolerance in transplantation and autoimmunity. Because of their robust immune inhibitory activities, there has been growing interest in MDSC-based cellular therapy. Various pre-clinical studies have demonstrated that the adoptive transfer of MDCS represented a promising therapeutic strategy for immune-related disorders. In this review, we summarize relevant studies of MDSC-based cell therapy in transplantation and autoimmune diseases and discuss the challenges and future directions for clinical application of MDSC-based cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.